Home Cart Sign in  
Chemical Structure| 149354-10-9 Chemical Structure| 149354-10-9

Structure of 149354-10-9

Chemical Structure| 149354-10-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 149354-10-9 ]

CAS No. :149354-10-9
Formula : C15H21NO3
M.W : 263.33
SMILES Code : O=C(N1CCC2=CC=C(O)C=C2CC1)OC(C)(C)C
MDL No. :MFCD12408171

Safety of [ 149354-10-9 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P261-P305+P351+P338

Application In Synthesis of [ 149354-10-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 149354-10-9 ]

[ 149354-10-9 ] Synthesis Path-Downstream   1~1

  • 1
  • [ 19745-07-4 ]
  • [ 149354-10-9 ]
  • [ 866939-13-1 ]
YieldReaction ConditionsOperation in experiment
Step 3: 1,1-Dimethylethyl 7-[(5-chloro-2-pyrazinyl)oxy]-1,2,4,5-tetrahydro-3H-3- benzazepine-3-carboxylate 1,1-Dimethylethyl 7-hydroxy-1, 2, 4, 5-tetrahydro-3H-3-benzazepine-3-carboxylate (Description 3 of WO 02/40471) (182mg, 0.69mmole) was dissolved in dry dimethylformamide (3ml), cooled to 0°C and treated with sodium hydride (60percent in mineral oil, 29mg, 0.72mmole). The mixture was allowed to warm to room temperature over 60 minutes. A solution of <strong>[19745-07-4]2,5-dichloropyrazine</strong> (product of E1, step 2) (112mg, 0.76mmole) in dry dimethylformamide (1 ml) was added and the mixture stirred at room temperature for 2 hours. The mixture was diluted with water (10ml) and extracted with ethyl acetate (x 2). The ethyl acetate layers were combined, dried under magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography eluting with ethyl acetate/pentane (1: 4) to afford the title compound (208mg). MS (ES+) m/e 376 [M+H]+.
Description 6 1,1-Dimethylethyl 7-[(5-ch loro-2-pyrazi nyl)oxy]-1,2,4,5-tetrahyd ro-3H-3-benzazepi ne- 3-carboxylate (D6); 1,1-Dimethylethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate (182 mg, 0.69 mmol: obtainable by the process described in Description 3 from WO 02/40471) was dissolved in dry dimethylformamide (3 ml), cooled in an ice bath and treated with sodium hydride (60 percent in mineral oil, 29 mg, 0.72 mmol). The mixture was allowed to warm to room temperature over 1 hour. A solution of <strong>[19745-07-4]2,5-dichloropyrazine</strong> (D5) (112 mg, 0.76 mmol) in dimethylformamide was added and the mixture stirred at room temperature for 2 hours and left to stand overnight under argon. The mixture was diluted with water and extracted with ethyl acetate (x 2). The ethyl acetate layers were combined, dried under magnesium sulfate and evaporated. The residue was purified by Biotage column chromatography, eluting with 1: 4 ethyl acetate: pentane to afford the title compound (208 mg). MS (ES+) m/e 376 [M+H]+.
 

Historical Records

Technical Information

Categories